CONCLUSION:
Incidence of new onset atrial fibrillation evidenced to be less frequent in patients with severe COVID-19 regardless of inflammatory burden, however it proves to be a marker of poor prognosis. Despite understanding the hypercoagulable milieu of the disease, the benefit of anticoagulation for prevention of stroke during the course of severe COVID-19 remains unclear. Furthers larger studies are warranted to assess the incidence of stroke associated with NOAF in severe COVID-19 infection.
FUNDING: None